A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2010-2011, When Administered to Elderly Subjects.
Phase of Trial: Phase II
Latest Information Update: 15 Feb 2016
At a glance
- Drugs Influenza virus vaccine; MF 59
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors Novartis
- 13 Dec 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Jul 2010 New trial record